9 results about "Cholesterol derivatives" patented technology

The invention provides ski wax compositions comprising a lipid component which is a cholesterol or a cholesterol derivative, a fatty acid or salt of a fatty acid, a diglyceride, or a combination thereof. It further provides ski wax compositions comprising squalene or a squalene derivative. The ski wax compositions according to the invention can be used as a glide wax or grip wax and may be applied directly to the base of a ski or to a ski skin.

The application belongs to the technical field of medical intermediates, and discloses application of a cholesterols derivative in preparation of a diabetes drug. It is found by the application that the cholesterols derivative has good alpha-glucosidase inhibiting activity by using an in-vitro pharmacological activity model for evaluation, and has potential to be developed into a new type of diabetes prevention or treatment drug.

The invention discloses a 7-site amino-acid ester-cholesteric derivative, the chemical structure of which is shown in the following formula: wherein the 7-site amino-acid ester-cholesteric derivative has an inhibition effect on human breast cancer cells, human ovarian cancer cells, human breast duct cancer cells and human cervical cancer cells, and can be used for preparing antitumor drugs.

The invention relates to the field of synthesis of organic fluorescent dyes, and discloses a conjugate of indocyanine green and cholesterol as well as synthesis and application of the conjugate. The conjugate is formed by connecting an indocyanine green derivative and a cholesterol derivative through an amido bond; the indocyanine green derivative is ICG-R-COOH; iCG is indocyanine green, R is-(CH2) nH. [I-], n is an integer of 1-6, or R is-(CH2) mSO3-, and m is 3 or 4; and the cholesterol derivative is cholesterole-NH2, beta-sitosterole-NH2, stigmasterole-NH2 or ergosterole-NH2. The invention also discloses a preparation method of the cholesterol derivative. The lipidosome constructed by the conjugate is high in stability, good in dispersity and strong in NIR-II fluorescence, the blood vessel and tumor imaging contrast ratio and definition under a 1300 nm near-infrared imaging window are superior to those of lipidosome constructed by commercial ICG, more excellent diagnosis and treatment performance is shown, and wide application prospects are achieved.

The invention relates to the technical field of nano-drugs, in particular to a glucocorticoid nano-emulsion for treating sepsis. The sialic acid-cholesterol derivative modified glucocorticoid nano-emulsion provided by the invention can remarkably improve the survival rate and the life quality of mice when being used for treating sepsis, and in a sepsis re-challenge pharmacodynamics experiment, under the condition that secondary drug treatment is not carried out, the survival rate of survived mice is high, and the survival rate of the survived mice is high. The risk of reinfection is greatly reduced, and guiding significance is provided for solving the problem that the death rate of sepsis survivors is high after the sepsis survivors are discharged from hospital clinically; meanwhile, the sialic acid-cholesterol derivative modified glucocorticoid nanoemulsion disclosed by the invention can also reduce the risk of secondary infection of diseases caused by pathogens containing LPS antigens in the organism.

The invention relates to the technical field of nano-drugs, in particular to sialic acid modified ibrutinib phospholipid complex nanoparticles capable of being used for treating sepsis. The sialic acid modified ibrutinib phospholipid complex nanoparticle prepared by the invention comprises ibrutinib, egg yolk phosphatidyl glycerol and a sialic acid-cholesterol derivative, and the nanoparticle can obviously improve the accumulation of a preparation at an inflammation part and the targeting of the preparation on inflammation-related macrophages; the BTK inhibitor has the advantages that the BTK inhibitor can be used for treating sepsis, so that the sepsis treatment effectiveness and safety of the BTK inhibitor are greatly improved, more importantly, sepsis survivor mice can be helped to relieve the immunosuppression state, strong immune memory is generated, the reinfection risk is greatly reduced, and the BTK inhibitor has guiding significance in solving the problem that the death rate of sepsis survivors is relatively high after the sepsis survivors are discharged from hospitals clinically; meanwhile, the sialic acid modified ibrutinib phospholipid complex nanoparticles can also reduce the risk of secondary infection of diseases caused by pathogens containing LPS antigens by the organism.

Targeted liposomes for delivery of protein degrading agents. In one embodiment, the targeting liposome includes a phospholipid, cholesterol or a cholesterol derivative, a PEG lipid, a targeting lipid, and a protein degradation agent. In other embodiments, the targeted liposomes include phospholipids, cholesterol or cholesterol derivatives, PEG lipids, targeted lipids, and a protein degrading agent-ligase complex. Also provided are kits for the preparation of targeted liposomes of protein degradation agents and / or protein degradation agent-ligase complexes. Methods of making such targeted liposomes are also provided.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a cholesterol derivative as well as a preparation method and application thereof. The chemical structural formula of the cholesterol derivative is shown in the specification. According to the cholesterol derivative, effective loading of mRNA can be achieved, the encapsulation efficiency of the cholesterol derivative to mRNA is 80% or above, compared with natural cholesterol, the cholesterol derivative has higher delivery efficiency when used for nucleic acid drug delivery, and the cholesterol derivative has good biocompatibility and pharmaceutical properties and can be used for preparing a nucleic acid drug. Good application prospects are realized in the field of development of drug delivery systems and drug preparations.

The invention relates to a method for preparing cells overexpressing exogenous genes through electrotransfection, which comprises the following steps: treating the cells with a cell electrotransfection pretreatment reagent before electrotransfection, and the cell electrotransfection pretreatment reagent contains cholesterol derivatives. The invention also relates to the exogenous gene overexpressed cell prepared by the method, application of the cell electrotransfection pretreatment reagent in preparation of the exogenous gene overexpressed cell, and a cell electrotransfection kit. The cell electrotransfection kit comprises a cell electrotransfection medium component and a cell treatment component. The cell treatment component comprises a cholesterol derivative. The method provided by the invention can greatly improve the survival rate of cells after electrotransfection and the proportion and quantity of cells with positive exogenous gene expression.